Fresenius Medical Care AG (NYSE:FMS) Stake Cut by VisionPoint Advisory Group LLC

VisionPoint Advisory Group LLC reduced its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,269 shares of the company's stock after selling 36,114 shares during the quarter. VisionPoint Advisory Group LLC's holdings in Fresenius Medical Care were worth $2,442,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Moran Wealth Management LLC increased its stake in Fresenius Medical Care by 47.0% during the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock valued at $4,971,000 after buying an additional 74,621 shares during the period. ABC Arbitrage SA acquired a new position in shares of Fresenius Medical Care during the fourth quarter valued at approximately $4,215,000. Quantinno Capital Management LP raised its holdings in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock worth $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Franklin Resources Inc. lifted its position in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company's stock worth $1,490,000 after purchasing an additional 2,386 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its stake in Fresenius Medical Care by 2.2% during the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company's stock valued at $1,456,000 after purchasing an additional 1,398 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company's stock.

Remove Ads

Fresenius Medical Care Price Performance

Shares of NYSE FMS traded up $0.15 during mid-day trading on Tuesday, reaching $23.46. The company had a trading volume of 203,911 shares, compared to its average volume of 248,286. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.25. The stock has a market cap of $13.77 billion, a PE ratio of 19.39, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average price of $23.39 and a two-hundred day moving average price of $21.74.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.07. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. On average, equities analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Berenberg Bank started coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price objective on the stock. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Truist Financial raised their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.